Critical Limb Ischemia Market Scope, Share Analysis And Growth 2025

Drawing from trusted sources and expert analysis, this report helps businesses navigate the complex landscape of the critical limb ischemia industry.

Critical Limb Ischemia Market Analysis & Forecast: 2025-2029
The critical limb ischemia market size has grown strongly in recent years. It will grow from $3.6 billion in 2024 to $3.89 billion in 2025 at a compound annual growth rate (CAGR) of 8.0%. The growth in the historic period can be attributed to increase in diabetes cases, tobacco consumption, hypertension prevalence, improvements in vascular imaging, growth in endovascular interventions, medical research and clinical trials.

The critical limb ischemia market size is expected to see strong growth in the next few years. It will grow to $5.52 billion in 2029 at a compound annual growth rate (CAGR) of 9.2%. The growth in the forecast period can be attributed to regenerative medicine advances, focus on early intervention, increasing prevalence of obesity, global health initiatives, patient education program. Major trends in the forecast period include wearable health technologies, telemedicine and remote patient monitoring, integration of artificial intelligence (AI), patient-centric care models, minimally invasive interventions.

Get your free sample today:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9859&type=smp

What Are The Factors Driving The Critical Limb Ischemia Market?
The rising incidence of diabetes mellitus and peripheral artery diseases is expected to propel the growth of the critical limb ischemia treatment market going forward. Diabetes mellitus refers to a metabolic disease condition that involves elevated levels of blood glucose. Peripheral artery disease refers to a condition where leg arteries are narrowed, reducing blood flow to the arms or legs. The likelihood of vascular complications and amputation is increased by diabetes and peripheral artery diseases, making them risk factors for causing critical limb ischemia. Therefore, the rising incidence of diabetes mellitus and peripheral artery diseases is driving the growth of the critical limb ischemia market. For instance, in January 2022, according to the International Diabetes Federation, a Belgium-based umbrella organization of national diabetes associations, the global diabetes prevalence is expected to increase by 12.2% (783.2 million) in 2045. Furthermore, in March 2023, according to the journal published by Oxford University Press, a UK-based university press of the University of Oxford, people with peripheral artery diseases are expected to increase by nearly 50% by 2045. Therefore, the growing adoption of cloud-based document processing services is driving the critical limb ischemia treatment market.

What Segments Are Covered In The Critical Limb Ischemia Market Report?
The critical limb ischemiamarket covered in this report is segmented –

1) By Type: Devices; Drugs; Surgery
2) By Medication: Antihypertensive Agents; Antiplatelet Drugs; Antithrombotic Agents; Other Medications
3) By Application: Hospital; Clinic; Other Applications

Subsegments:
1) By Devices: Angioplasty Balloons; Stents; Catheters; Atherectomy Devices; Implantable Devices
2) By Drugs: Antiplatelet Agents; Vasodilators; Anticoagulants; Thrombolytics; Growth Factors And Cytokines
3) By Surgery: Bypass Surgery; Endarterectomy; Amputation; Revascularization Procedures

What Are The Main Trends, Positively Impacting The Growth Of Critical Limb Ischemia Market?
Major companies operating in the critical limb ischemia (CLI) treatment market are innovating technologically advanced products, such as dissolving stents, to improve treatment outcomes for patients suffering from this severe form of peripheral artery disease. Dissolving stents, also known as bioresorbable stents, are designed to provide temporary support to the affected artery and then gradually dissolve after the vessel has healed. For instance, in April 2024, Abbott Laboratories, a US-based medical device company, received approval from the Food and Drug Administration (FDA), a US-based federal agency, for the Esprit BTK Everolimus Eluting Resorbable Scaffold System. It is a dissolving stent designed for patients suffering from chronic limb-threatening ischemia (CLTI) in arteries below the knee. This marks the first approval of a dissolving stent specifically for this condition in the United States. The stent is made from materials similar to dissolving sutures and is designed to gradually dissolve over approximately three years after implantation. It releases the immunosuppressive drug everolimus, which helps prevent the re-narrowing of arteries and supports vessel healing.

Which Are The Major Players Operating In The Global Critical Limb Ischemia Market?
Major companies operating in the critical limb ischemia market include Medtronic Plc, Boston Scientific Corporation, ThermoGenesis Holdings Inc., Abbott Laboratories, Pluri Biotech Ltd., Rexgenero Ltd., LimFlow SA, Micro Medical Solutions, Cardiovascular Systems Inc., Cynata Therapeutics Ltd, Shanghai MicroPort Medical (Group) Co Ltd., B. Braun SE, Teva Pharmaceutical Industries Ltd., Aldagen Inc., Cook Medical, Philips, BD, Penumbra Inc., Cardinal Health Inc., Teleflex Incorporated, AngioDynamics Inc., Endologix Inc., Terumo Corporation, Teleflex, MicroPort Scientific, Silk Road Medical, LeMaitre Vascular Inc., Merit Medical Systems Inc., Shockwave Medical, Avinger, Biomerics LLC, Intact Vascular Inc., Soundbite Medical Solutions, Bluegrass Vascular Technologies, PQ Bypass, Vasorum Ltd, Rex Medical, Otsuka Medical Devices, Aortica Corporation

View the full critical limb ischemia market report here:
https://www.thebusinessresearchcompany.com/report/critical-limb-ischemia-global-market-report

Critical Limb Ischemia Market Regional Insights:
North America was the largest region in the critical limb ischemia treatment market in 2024. The regions covered in the critical limb ischemia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Contact Us:

The Business Research Company

https://thebusinessresearchcompany.com/

Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267

Email: info@tbrc.info


Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company